CXCL16 and pachyonychia congenita: Collectively, our data highlight ZEB1 as a central regulator modulating the efficacy of immunotherapy and gemcitabine in PC through its epigenetic regulation of CXCL16 expression and the intratumoral balance of CD8+ T cells and neutrophils (Figure 7F).